



2022 BLOOM BURTON AWARD GALA

FOUR SEASONS HOTEL TORONTO
SEPTEMBER 29, 2022

PROGRAM



CONTENT

- 02** Welcome from Bloom Burton & Co.
- 03** Agenda
- 04** Welcome from Carl Hansen
- 06** Message from the Prime Minister
- 08** Message from the Premier of Ontario
- 10** Message from the Mayor of Toronto
- 12** Finalists
- 23** Judges
- 30** Table Sponsors

WELCOME!

FROM BLOOM BURTON & CO.

Thank you for joining us at the 2022 Bloom Burton Award Gala! This is the sixth edition of the Bloom Burton Award and the first year we are all back in person – after two years of virtual celebrations – to shine a spotlight on exceptional leaders in the Canadian healthcare sector.

The Bloom Burton Award celebrates those people who demonstrate excellence in the healthcare field and is given to an individual in any role, from any field of healthcare, and at any stage of development for their amazing and impactful work in the immediately preceding year. It's time to recognize and celebrate those who advance medical science, attract or provide risk capital, launch new products or companies, or change policy with a dramatic and positive impact on the world stage.

We received many nominations from the public at large and our international and esteemed judging panel has narrowed down nominees to the following luminary finalists, in alphabetical order:

- o Frank Baylis, Executive Chairman, and Kris Shah, President, Baylis Medical Technologies
- o Pieter Cullis, Co-Founder, Acuitas Therapeutics
- o Jan Skvarka, former President and Chief Executive Officer, Trillium Therapeutics

We hope that you will be astounded and inspired by the individuals above. We would also like you to raise a glass and toast their achievements with us!

Brian Bloom & Jolyon Burton



AGENDA

6:00 PM

Cocktail Reception

7:00 PM

**Bloom Burton Award Program
and Dinner**

Welcome remarks from
Brian Bloom and Jolyon Burton

Celebrating Frank Baylis & Kris Shah
Celebrating Pieter Cullis
Celebrating Jan Skvarka

Remarks and winner announcement by
Carl Hansen

10:00 PM

Networking and Entertainment

MESSAGE FROM CARL HANSEN

2021 BLOOM BURTON AWARD WINNER

Dear Colleagues,

It is my distinct pleasure to welcome you all to the 2022 Bloom Burton Award Gala.

We gather here tonight to recognize excellence. This year's finalists have distinguished themselves through achievement in the business of life sciences innovation. They have succeeded on the world stage and their success brings honour to Canada and to our sector.



Tonight's finalists include world-class science and business leaders. Each has dedicated his efforts and talents to solving the tough practical problems that stand on the path between basic science and the delivery of products that improve the lives of people around the world.

No one person can do this alone. My sincere congratulations not only to them as individuals, but also to their teams, communities and families that support them.

It has been several years since we have been able to gather in person, and I'd like to thank Brian, Jolyon and the Bloom Burton team, and our distinguished judges for making this event possible and continuing to champion the important work being done here in Canada.

I have always believed in our country's potential to lead at the cutting edge of the life sciences industry. We can be a global force. Although we are not there yet, the opportunity has never been more clear, and the urgency to seize it has never been greater.

To fully realize our potential, many of our institutions will need to work together. Our Universities must recognize the needs of a changing economy and hold the bar high in training the next generation of scientists and engineers. Our companies and investors will need to keep pace with a rapidly changing world and avoid the trap of cynicism and small- or short-term thinking. The public sector, in turn, should look for opportunities to support innovation through strong and sustainable partnerships with industry. Even more, we need to discover and implement the policies that unlock innovation, that attract investment and talent, and, above all, that ensure we capture the value of our work here in Canada.

If we do this, the result will be a strong and growing ecosystem of global companies, companies that serve as the engine for our economy while delivering products that reach millions of people around the world. I see a future where life science has matured into a power center of our future prosperity and a source of pride for our country.

What we will always need are those special individuals that provide the spark of innovation and leadership. As tonight's finalists have shown, Canada has the talent.

I wish you all an excellent evening and look forward to celebrating our finalists.

Sincerely,

Carl Hansen
CEO & President
AbCellera



The Rt. Hon. Justin P.J. Trudeau, P.C., M.P.

Prime Minister of Canada



PRIME MINISTER • PREMIER MINISTRE

Message from the Prime Minister of Canada

It is with great pleasure that I welcome you all to the 2022 Bloom Burton Award Gala.

In the face of great challenges, the resiliency and creativity of Canadians, including scientists, inventors, and entrepreneurs, is staggering. I would like to recognize the leadership of all finalists for the 2022 Bloom Burton Award. Indeed, the COVID-19 pandemic has presented numerous hardships, and our innovative healthcare industry is more important than ever. As you come together to honour those who have undertaken important work to keep Canadians safe, let us unite in our commitment to build a brighter, healthier future for everyone.

This event offers a wonderful occasion for those working in the healthcare industry to reflect on their important – and numerous – contributions.

Please accept my warmest welcome and best wishes for a memorable gala!

Ottawa
2022



Doug Ford

Premier of the Province of Ontario



Premier of Ontario - Premier ministre de l'Ontario

September 29, 2022

A MESSAGE FROM PREMIER DOUG FORD

Hello and good evening to everyone taking part in the Bloom Burton Award Gala. Tonight, we gather to recognize the scientists, inventors, entrepreneurs, policy makers and leaders who made the greatest contributions to Canada's health care sector in the past year.

I want to congratulate this year's finalists: Frank Baylis and Kris Shah of Baylis Medical Technologies, Pieter Cullis of the University of British Columbia, and Jan Skvarka of Trillium Therapeutics. We have some of the best minds working in our health care industry, and your achievements are proof of that.

I applaud the people at Bloom Burton & Co. for organizing this terrific event. Your commitment to celebrating excellence in the Canadian health care sector helps build a culture that rewards the pursuit of knowledge and innovation.

As you know, Ontario's life sciences ecosystem supports thousands of good-paying, high-skilled jobs in communities across our province. Our government will continue working to unlock the full potential of the sector, support innovation and new technologies, and enhance companies' competitiveness at home and on the global stage.

Have a memorable gala.

A handwritten signature in black ink, appearing to read "Doug Ford".

Doug Ford
Premier



John Tory
Mayor of Toronto



Message from the Mayor

It is my pleasure to extend greetings and a warm welcome to everyone attending the 2022 Bloom Burton Award Gala.

Congratulations to this year's award recipients who are being recognized for their significant contributions to Canada's innovative healthcare sector. Your valued contributions will shape the future of Canada's healthcare industry, and will help pave the way for future innovation.

The City of Toronto is proud of organizations and individuals that are committed to making a difference and recognizes their contributions to the economic and social well-being of our communities. Your tremendous efforts and talents impact the lives of many and make our city better.

On behalf of Toronto City Council, I thank the organizers and wish everyone an informative and enjoyable event.

Yours truly,

A handwritten signature in blue ink, which appears to read "John Tory". The signature is fluid and cursive.

John Tory
Mayor of Toronto

“ We look forward to celebrating this year’s finalists – Frank Baylis and Kris Shah, Pieter Cullis and Jan Skvarka.....

Frank Baylis and Kris Shah are being nominated for growing Baylis Medical into Canada’s largest domestic medical device manufacturer, and for monetizing its core cardiovascular business to Boston Scientific for US\$1.75 billion.

Pieter Cullis developed lipid nanoparticle systems that contributed to the approval of four novel, approved drugs, in addition to the Pfizer-BioNTech Covid-19 vaccine.

Finally, in late 2019, Jan Skvarka joined and turned around a struggling Trillium Therapeutics, which was ultimately acquired by Pfizer for approximately US\$2.26 billion, a 46x increase in stock price and 140x increase in market cap during his tenure.

”

Brian Bloom
Chairman and CEO of Bloom Burton & Co.

FINALISTS



Frank Baylis

Baylis Medical Technologies



Kris Shah

Baylis Medical Technologies



Pieter Cullis

Acuitas Therapeutics



Jan Skvarka

(Formerly) Trillium Therapeutics

14 Finalists



Frank Baylis

Baylis Medical Technologies

#BBAWARD2022

FRANK BAYLIS

Executive Chairman, Baylis Medical Technologies

Frank Baylis joined Baylis Medical in 1989, serving as its President until 2015. During his presidency, the company grew into an internationally recognized developer of medical devices used in cardiac electrophysiology, structural heart disease, and spine procedures. He returned to Baylis Medical Company in 2019 after serving as Liberal Member of Parliament for the federal riding of Pierrefonds-Dollard from 2015 to 2019. Frank also co-founded the consulting business OME Group in 1991, which was sold to Ernst and Young in 2011.

Currently, Frank is the Executive Chairman of Baylis Medical Technologies' Board of Directors, a leader in the development and commercialization of innovative medical devices in the fields of interventional radiology and spine procedures. Headquartered in Canada, the company also provides contract manufacturing services to some of the world's leading medical device companies.

Frank is an active board member for Epineuron Technologies. In the past he has served on the boards of MEDEC, Campus de Technologie de Sante (CTS), and the Business Advisory Committee of HTX. His list of accomplishments includes several patents, the Ernst and Young Entrepreneur Award for Healthcare in Quebec (2011) and the University of Waterloo Alumni Achievement Award (2014).

Frank has a B.Sc. in Electrical Engineering from the University of Waterloo.

16 Finalists



Kris Shah

Baylis Medical Technologies

#BBAWARD2022

KRIS SHAH

President, Baylis Medical Technologies

Kris joined Baylis Medical Company in 1990 and served as president from 2015 until the company was acquired by Boston Scientific in 2022. Baylis Medical Company is a leading developer, manufacturer, and distributor of specialized medical devices for interventional cardiology. The company had previously divested its Interventional Pain Management business to Kimberly Clark (now Avanos) in 2009, and its Bone Tumor Ablation business (OsteoCool) to Medtronic in 2016. Kris also co-founded the consulting business OME Group in 1991, which was sold to Ernst and Young in 2011.

Kris Shah is currently the president of Baylis Medical Technologies, a leader in the development and commercialization of innovative medical devices in the fields of interventional radiology and spine procedures. Headquartered in Canada, the company also provides contract manufacturing services to some of the world's leading medical device companies.

Kris is an active board member for AdvaMed Accel and Intellijoint Surgical. In the past he has served on the boards of Venture Lab, MEDEC, and the Business Advisory Committee of HTX and Conavi Medical. His list of accomplishments includes numerous patents, the Ernst and Young Entrepreneur Award for Healthcare in Quebec (2011) and the University of Waterloo Alumni Achievement Award (2014).

Kris has a B.Sc. in Electrical Engineering from the University of Waterloo.

18 Finalists



Pieter Cullis

Acuitas Therapeutics

#BBAWARD2022

PIETER CULLIS

Co-Founder, Acuitas Therapeutics

Pieter R. Cullis, PhD, FRSC, FNAI (USA), OC, Director, Nanomedicines Research Group, Professor, Department of Biochemistry and Molecular Biology, University of British Columbia.

Dr. Cullis and co-workers have been responsible for fundamental advances in the development of nanomedicines employing lipid nanoparticle (LNP) technology for cancer therapies, gene therapies and vaccines. This work has contributed to five drugs that have received clinical approval by the FDA, the European EMA and Health Canada. Dr. Cullis has also co-founded eleven biotechnology companies that now employ over 400 people, has published over 350 scientific articles (h index 129) and is an inventor on over 100 patents. He has also co-founded and been Founding Scientific Director of two National Centre of Excellence networks, the Centre for Drug Research and Development (now AdMare) in 2004 and the NanoMedicines Innovation Network in 2019. These not-for-profit networks are aimed at translating basic research in the life sciences into commercially viable products and have given rise to numerous start-up companies.

Dr. Cullis has received many awards including the Order of Canada in 2021 and the VinFuture Prize (Vietnam), the Prince Mahidol Award (Thailand), the Gairdner International Award (Canada) and the Tang Prize (Taiwan) in 2022. Two recently approved drugs that are enabled by LNP delivery systems devised by Dr. Cullis, members of his UBC laboratory and colleagues in the companies he has co-founded deserve special emphasis. The first is Onpattro which was approved by the US FDA in August 2018 to treat the previously fatal hereditary condition transthyretin-induced amyloidosis (hATTR). Onpattro is the first RNAi drug to receive regulatory approval. The second is Comirnaty, the COVID-19 mRNA vaccine developed by Pfizer/BioNTech that has received regulatory approval in many jurisdictions including Canada, the USA, the UK and Europe. Comirnaty is playing a major role in containing the global Covid-19 pandemic with approximately 3B doses administered worldwide in 2021.

20 Finalists



Jan Skvarka
(Formerly) Trillium Therapeutics

#BBAWARD2022

JAN SKVARKA

Former President and Chief Executive Officer, Trillium Therapeutics

Jan Skvarka is Executive Chairman of DEM Biopharma, a discovery stage immuno-oncology company, and GentiBio, a leading pre-clinical stage Tregs cell therapy company focused on autoimmune diseases.

From 2019-21, Jan was the Chief Executive Officer of Trillium Therapeutics (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company. At Trillium, he led a highly successful turn-around, taking a struggling company with a \$16M market capitalization to a \$2.3B acquisition by Pfizer in two years.

Previously, Jan served as Chief Executive Officer of Tal Medical, a clinical-stage neuroscience company, and a lead partner in the Healthcare Practice at Bain & Company, where he advised leading life sciences companies on strategy, operational improvement and M&A. He started his career in corporate finance with Price Waterhouse in London, UK, and Vienna, Austria. Jan holds an MBA degree from Harvard Business School.



SAVE THE DATE

for the return of the annual Bloom Burton & Co. Holiday Party!

JOIN US ON
NOVEMBER 30, 2022
FOR HOLIDAY CHEERS!



MORE DETAILS TO COME

JUDGING PANEL

Michael Altman

Managing Director,
Perceptive Advisors

Christopher Arendt

Head,
Oncology Therapeutic Area Unit,
Takeda

Karen Bernstein

Co-Founder & Chairman,
BioCentury Inc.

Carl Gordon

Managing Partner,
OrbiMed Advisors

Dennis Purcell

Founder & Senior Advisor,
Aisling Capital

Melinda Richter

Global Head,
Johnson & Johnson Innovation,
JLABS

Camille Samuels

Partner,
Venrock



JUDGES



Michael Altman

Managing Director, Perceptive Advisors

Michael Altman joined Perceptive in 2007 and is a managing director on the investment team. His focus is on medical devices, diagnostics, digital health and specialty pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Additionally, Michael serves as the CFO and Director of ARYA Sciences Acquisition Corp II & III.

Christopher Arendt

Head, Oncology Therapeutic Area Unit, Takeda

Based at Takeda's Cambridge, Massachusetts, R&D campus, Dr. Arendt is responsible for oversight of Takeda's global Oncology Development portfolio. Since joining Takeda in 2015, Dr. Arendt has helped reshape Takeda's Oncology pipeline with a strong network of global collaborators, emphasizing emerging science leveraging immunological modalities and mechanisms towards curative-intent cancer medicines.



JUDGES



Karen Bernstein

Co-Founder & Chairman, BioCentury Inc.

Karen is Co-Founder and Chairman of BioCentury Inc. and was Editor in Chief from October 1992 to August 2015. She is a director at Ovid Therapeutics Inc., which is developing drugs for orphan diseases of the brain, and at Codiak Biosciences Inc., which is engineering exosomes to target new therapeutic spaces. Karen also serves on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences and is a member of the board of advisors of KGI's School of Pharmacy. She serves on the Board of Overseers of Scripps Research.

Carl Gordon

Managing Partner, OrbiMed Advisors

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. In recent years, Forbes® Magazine named Dr. Gordon one of the top 100 venture capitalists in the world when it placed him on the "Forbes Midas List".



JUDGES



Dennis Purcell

Founder & Senior Advisor, Aisling Capital

Mr. Purcell is the original Founder of Aisling Capital LLC. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc. Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.

Melinda Richter

Global Head, Johnson & Johnson Innovation — JLABS

As Global Head of Johnson & Johnson Innovation, JLABS (JLABS), Melinda Richter fosters the Johnson & Johnson Family of Companies external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award-winning firm dedicated to accelerating research to the patient. Melinda also held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing.



JUDGES



Camille Samuels

Partner, Venrock

Camille Samuels focuses on healthcare with an emphasis on biotech, medical devices, and consumer health. She currently serves on the board of Biolux, Corvidia, Iris, Unity (UBX), and XCaliber. Prior to Venrock, Camille was a Managing Director at Versant Ventures where she served on the board (or as a board observer) at many companies including Genomic Health (GHDX), Jazz (JAZZ), Kythera (KYTH), Novacardia (acquired by Merck), and ParAllele (acquired by Affymetrix). Before Versant, she was responsible for business development at Tularik (acquired by Amgen). During her early career, Camille worked in corporate development at Genzyme and Millennium Predictive Medicine and was a management consultant at LEK Consulting.



Our esteemed panel of judges
are respected international
leaders in healthcare
investment, entrepreneurship
and journalism.



30 Sponsors

THANK YOU

Table Sponsors



CPPOINT CAPITAL



#BBAWARD2022



Half-Table Sponsors



WE APPRECIATE YOUR SUPPORT!

BBHIC 2023





bloom burton & co

/accelerating returns in healthcare®

**BLOOM BURTON & CO.
HEALTHCARE INVESTOR CONFERENCE**

April 25-26, 2023

#BBHIC2023

Tomorrow, September 30, 2022, is National Truth and Reconciliation Day and we would like to acknowledge the land on which the 2022 Bloom Burton Award Gala takes place as the traditional land of the Anishinabewaki, Wendake-Nionwentsio, Haudenosaunee, and the Mississaugas of the Credit.

Today, this meeting place is still the home to many Indigenous people from across Turtle Island and we are grateful to have the opportunity to work and host on this land.







#BBAWARD2022